What we do
Most haemostasis testing in Australia still relies on plasma-based methods. Haemoview Diagnostics enables whole blood analysis with sample volumes as low as 300 µL — delivering faster, more complete coagulation insights for hospitals and veterinary practices alike.
We're home to the only open viscoelastic and platelet function testing systems on the market — giving clinicians and researchers the flexibility to run our validated test menu or develop and run their own.
For Researchers & Clinical Scientists
Rich data output for observational and outcomes-based research
Freedom to design your own protocols
For Clinicians
Real-time support for clinical decision-making — with a comprehensive test portfolio covering bleeding, thrombosis, fibrinolysis, and DOAC monitoring for deeper coagulation insights
For Laboratory Professionals
Reliable whole blood analysis with minimal sample volumes with full quality control support
Viscoelastometry
Transitioning to MultiClot
ClotPro has now been superseded by MultiClot, with full ANZ availability expected in late 2026.
MultiClot® is the next-generation viscoelastic testing platform — offering everything ClotPro users are familiar with.
The next generation of whole-blood viscoelastic testing. MultiClot's industry-leading test menu — including assays for DOACs, fibrinolysis, and antifibrinolytics — reveals coagulation dynamics that standard systems miss.
Developed by the team behind both ClotPro and Multiplate — MultiClot utilises cup and pin technology to deliver unmatched flexibility and a superior test menu, including newly developed assays for enhanced detection of thrombosis, fibrinolysis, DOAC effects, and antifibrinolytic activity.
Importantly, MultiClot reagents and consumables are fully compatible with the current ClotPro device — protecting your existing investment while you transition.
APIRO's MultiClot-compatible reagents are now TGA approved for clinical use on your current ClotPro device — giving existing ClotPro users access to the expanded test menu today, ahead of the full MultiClot platform launch in ANZ in late 2026
Platelet Function
The Multiplate® system is the leading platform for whole-blood platelet function testing — assessing platelet activity and evaluating the efficacy of antiplatelet therapies to support clinical decision-making and improve patient outcomes.
Using small volumes of whole blood eliminates time-consuming centrifugation, delivering reliable results in just 10 minutes.
Platelet function testing supports clinical decision-making in:
-
Percutaneous Coronary Interventions (PCI)
-
Pre- and post-cardiac surgery assessment
-
De-escalation and monitoring of antiplatelet treatment
-
Heparin Induced Thrombocytopenia (HIT)
-
Patient Blood Management (PBM) programs
-
Therapeutic window monitoring for antiplatelet agents
For Researchers & Clinical Scientists:
-
Observational and outcomes-based platelet function research
-
Flexible, open testing protocols with rich data output
-
Investigation of novel antiplatelet therapies and thrombotic conditions
DOACs
DOASENSE is a single-use, point-of-care urine dipstick test with a high negative predictive value for detecting direct oral anticoagulants (DOACs) — delivering a rapid, reliable result when anticoagulation status is clinically urgent.
Designed for point-of-care applications, DOASENSE swiftly identifies significant DOAC levels in urine without laboratory processing — broadening eligibility assessment for thrombolysis and targeted reversal therapy in time-critical situations such as acute stroke.
Its simplicity, speed, and clinical reliability make DOASENSE an essential tool for emergency departments, stroke units, and any setting where DOAC status must be established rapidly